A new study published in Clinical
Rheumatology exposes how vaccine manufacturers used phony placebos in
clinical trials to conceal a wide range of devastating risks associated
with HPV vaccines.
Instead of using genuine inert placebos and comparing health impacts
over a number of years, as is required for most new drug approvals,
Merck and GlaxoSmithKline spiked their placebos with a neurotoxic aluminum adjuvant and cut observation periods to a matter of months.
Researchers from Mexico’s National Institute of Cardiology pored over 28
studies published through January 2017—16 randomized trials and 12
post-marketing case series—pertaining to the three human papillomavirus
(HPV) vaccines currently on the market globally.
In their July 2017 peer-reviewed report,
the authors, Manuel Martínez-Lavin and Luis Amezcua-Guerra, uncovered
evidence of numerous adverse events, including life-threatening
injuries, permanent disabilities, hospitalizations and deaths, reported
after vaccination with GlaxoSmithKline’s bivalent Cervarix vaccine and
Merck’s quadrivalent or nine-valent HPV vaccines (Gardasil and Gardasil
9) | |
|
No comments:
Post a Comment